Trimetazidine attenuates high-altitude fatigue and cardiorespiratory fitness impairment: A randomized double-blinded placebo-controlled clinical trial

Trimetazidine attenuates high-altitude fatigue and cardiorespiratory fitness impairment : A randomized double-blinded placebo-controlled clinical trial / Jie Yang, Laiping Zhang, Chuan Liu, Jihang Zhang, Shiyong Yu, Jie Yu, Shizhu Bian, Sanjiu Yu, Chen Zhang, Lan Huang

  • Biomedicine & Pharmacotherapy 116 (2019, August), 109003
  • PMID: 31125823
  • DOI: 10.1016/j.biopha.2019.109003


Abstract

Trimetazidine (TMZ) has been shown to optimize myocardial energy metabolism and is a common anti-ischemic agent. Our trial (ChiCTR-TRC-13003298) aimed to explore whether TMZ has any preventive effect on high-altitude fatigue (HAF), cardiac function and cardiorespiratory fitness upon acute high-altitude exposure and how it works on HAF. Thirty-nine healthy young subjects were enrolled in a randomized double-blinded placebo-controlled trial and were randomized to take oral TMZ (n = 20) or placebo (n = 19), 20 mg tid, 14 days prior to departure until the end of study. The 2018 Lake Louise Score questionnaire, echocardiography, assessments of physical working capacity, circulating markers of myocardial energy metabolism and fatigue were performed both before departure and arrival at highland. At follow-up, TMZ significantly reduced the incidence of HAF (p = 0.038), reversed cardiorespiratory fitness impairment, decreased left ventricular end-systolic volume (LVESV, p = 0.032) and enhanced left ventricular ejection fraction (LVEF, p = 0.015) at highland. Relative to the placebo group, the TMZ group had significantly lower LDH (p = 0.025) and lactate levels before (p < 0.001) and after (p = 0.012) physical exercise after acute high-altitude exposure. Additionally, improved left ventricular systolic function might have contributed to ameliorating HAF during TMZ treatment (LVEF, OR = 0.859, 95% CI = 0.741-0.996, p = 0.044). In conclusion, our results demonstrated that TMZ could prevent HAF, cardiorespiratory fitness impairment and improves left ventricular systolic function during acute high-altitude exposure. This trial provides new insights into the effect of TMZ and novel evidence against HAF and cardiorespiratory fitness impairment at highland.

Original document

Parameters

Science
Research / Study
Date
21 May 2019
People
Bian, Shizhu
Huang, Lan
Liu, Chuan
Yang, Jie
Yu, Jie
Yu, Sanjiu
Yu, Shiyong
Zhang, Chen
Zhang, Jihang
Zhang, Laiping
Country
China
Language
English
Other organisations
Army Medical University, China
Doping classes
S4. Hormone And Metabolic Modulators
Substances
Trimetazidine
Medical terms
Health / performance effects
Various
High altitude training
Document category
Scientific article
Document type
Pdf file
Date generated
22 May 2024
Date of last modification
27 May 2024
Category
  • Legal Source
  • Education
  • Science
  • Statistics
  • History
Country & language
  • Country
  • Language
Other filters
  • ADRV
  • Legal Terms
  • Sport/IFs
  • Other organisations
  • Laboratories
  • Analytical aspects
  • Doping classes
  • Substances
  • Medical terms
  • Various
  • Version
  • Document category
  • Document type
Publication period
Origin